CO:01:1 | Efficacy and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study of 115 patients: Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Veronica Batani1, Jasmin Mahajne1, Lorenzo Dagna1, Emanuel Della Torre1. | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale San Raffaele, Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University, Munich, Germany. Reumatismo [Internet]. 2025 Nov. 25 [cited 2026 May 25];77(s1). Available from: https://www.reumatismo.org/reuma/article/view/1961